CD276 and glioblastoma: CAR-Vδ1 were then tested against a range of antigen-positive and negative hematological and solid tumor targets: B7H3-negative Jurkat cells, and B7H3-positive cell lines U87 (originating from glioblastoma) and LAN-1 cells (Figure 3D).